Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Nov 1;84(3):e271-7.
doi: 10.1016/j.ijrobp.2012.04.019. Epub 2012 May 30.

External beam accelerated partial-breast irradiation using 32 gy in 8 twice-daily fractions: 5-year results of a prospective study

Itai M Pashtan  1 , Abram Recht, Marek Ancukiewicz, Elena Brachtel, Rita F Abi-Raad, Helen A D'Alessandro, Antonin Levy, Jennifer Y Wo, Ariel E Hirsch, Lisa A Kachnic, Saveli Goldberg, Michelle Specht, Michelle Gadd, Barbara L Smith, Simon N Powell, Alphonse G Taghian
Affiliations
Clinical Trial

External beam accelerated partial-breast irradiation using 32 gy in 8 twice-daily fractions: 5-year results of a prospective study

Itai M Pashtan et al. Int J Radiat Oncol Biol Phys. .

Abstract

Purpose: External beam accelerated partial breast irradiation (APBI) is an increasingly popular technique for treatment of patients with early stage breast cancer following breast-conserving surgery. Here we present 5-year results of a prospective trial.

Methods and materials: From October 2003 through November 2005, 98 evaluable patients with stage I breast cancer were enrolled in the first dose step (32 Gy delivered in 8 twice-daily fractions) of a prospective, multi-institutional, dose escalation clinical trial of 3-dimensional conformal external beam APBI (3D-APBI). Median age was 61 years; median tumor size was 0.8 cm; 89% of tumors were estrogen receptor positive; 10% had a triple-negative phenotype; and 1% had a HER-2-positive subtype. Median follow-up was 71 months (range, 2-88 months; interquartile range, 64-75 months).

Results: Five patients developed ipsilateral breast tumor recurrence (IBTR), for a 5-year actuarial IBTR rate of 5% (95% confidence interval [CI], 1%-10%). Three of these cases occurred in patients with triple-negative disease and 2 in non-triple-negative patients, for 5-year actuarial IBTR rates of 33% (95% CI, 0%-57%) and 2% (95% CI, 0%-6%; P<.0001), respectively. On multivariable analysis, triple-negative phenotype was the only predictor of IBTR, with borderline statistical significance after adjusting for tumor grade (P=.0537).

Conclusions: Overall outcomes were excellent, particularly for patients with estrogen receptor-positive disease. Patients in this study with triple-negative breast cancer had a significantly higher IBTR rate than patients with other receptor phenotypes when treated with 3D-APBI. Larger, prospective 3D-APBI clinical trials should continue to evaluate the effect of hormone receptor phenotype on IBTR rates.

Trial registration: ClinicalTrials.gov NCT00694577.

PubMed Disclaimer

Figures

Figure I
Figure I
Overall rate of local control.
Figure II
Figure II
Ipsilateral breast tumor recurrence rate by triple-negative status.
Figure III
Figure III
Distinct locations of a treatment scar and a recurrent tumor on MRI. (The circles denote the location of the initial and recurrent tumors.)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Beitsch PD, Shaitelman SF, Vicini FA. Accelerated partial breast irradiation. J Surg Oncol. 2011;103:362–368. - PubMed
    1. Berrang TS, Olivotto I, Kim DH, et al. Three-year outcomes of a canadian multicenter study of accelerated partial breast irradiation using conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2011;81:1220–1227. - PubMed
    1. Vicini F, Winter K, Wong J, et al. Initial efficacy results of RTOG 0319: three-dimensional conformal radiation therapy (3D-CRT) confined to the region of the lumpectomy cavity for stage I/ II breast carcinoma. Int J Radiat Oncol Biol Phys. 2010;77:1120–1127. - PMC - PubMed
    1. Polgar C, Fodor J, Major T, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma--5-year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69:694–702. - PubMed
    1. Vaidya JS, Joseph DJ, Tobias JS, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010;376:91–102. - PubMed

Publication types

MeSH terms

Associated data